IN FOCUS: Viiv Healthcare's Tivicay offers new HIV treatment option for patients

3 February 2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Viiv, set up by UK pharma major GlaxoSmithKline (LSE: GSK) with US drugmaker Pfizer (NYSE: PFE) and Shionogi (TYO: 4507), announced the launch of Tivicay (dolutegravir) at a briefing in London this morning attended by HIV/AIDS commentators and stakeholders.

The integrase inhibitor is indicated for use in combination with other antiretroviral agents in people with HIV. Its convenient once-daily dose, to be taken with or without food, is hoped to revolutionize treatment for those living with HIV. It has proven efficacy in treatment-naïve patients, as well as in those who have developed resistance to multiple HIV drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK